Allogene Therapeutics Halts Enrollment in Leukemia Trial Cema-Cel Due to Slow Recruitment
Key Insights
Allogene Therapeutics stopped enrolling patients in its Phase 1 trial of cemacabtagene ansegedleucel (cema-cel) for relapsed or refractory chronic lymphocytic leukemia (search) (CLL (search)).
The decision was driven by slower-than-expected recruitment, influenced by the emergence of new treatment options for CLL (search) patients.
Allogene is reallocating resources to other ongoing programs, focusing on advancing its broader pipeline of innovative therapies.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) has ceased patient enrollment in the Phase 1 clinical trial cohort evaluating cemacabtagene ansegedleucel (cema-cel) for treating relapsed or refractory chronic lymphocytic leukemia (search) (CLL (search)), effective Monday. The decision comes as recruitment rates lagged expectations, influenced by the increasing availability of alternative treatments for this patient population.
Strategic Shift
According to the company's recent 8-K filing with the Securities and Exchange Commission, this strategic shift allows Allogene to optimize resource allocation towards other ongoing programs. While investigators showed strong interest and recognized the need for additional treatment options for CLL (search) patients who have undergone BTKi and BCL2i therapies, the company is prioritizing its broader pipeline.
Ongoing Programs and Financial Stability
Allogene remains focused on developing innovative therapies and advancing its pipeline. H.C. Wainwright recently maintained a Buy rating on Allogene, with a steady price target of $9.00, following encouraging data from the TRAVERSE trial, which explores ALLO-316 in treating adult patients with CD70 (search)+ advanced renal cell carcinoma (search), showing promising results with a 38% objective response rate. The company's ALPHA3 (search) trial for cema-cel, which targets large B cell lymphoma (search), is progressing with over half of the sites activated.
In the Third Quarter 2024 Earnings Call, Allogene disclosed a net loss of $66.3 million but maintains a robust cash balance of $403.4 million, expected to extend into the second half of 2026. ALLO-316 has also demonstrated a 50% best overall response rate in renal cell carcinoma (search) patients, and the company is preparing for an IND filing for ALLO-329, targeting autoimmune diseases (search), expected in Q1 2025.
Financial Insights
Allogene's market capitalization stands at $570.31 million. InvestingPro Tips highlight that Allogene is "quickly burning through cash" and "not profitable over the last twelve months," which may have influenced the decision to reallocate resources. However, Allogene "holds more cash than debt on its balance sheet," and "liquid assets exceed short term obligations," suggesting financial stability to support strategic pivots. The company's operating income margin is -1,222,168.18% for the last twelve months as of Q3 2024.